KR101553292B1 - Composition for preventing or treating hyperosmia - Google Patents
Composition for preventing or treating hyperosmia Download PDFInfo
- Publication number
- KR101553292B1 KR101553292B1 KR1020130134096A KR20130134096A KR101553292B1 KR 101553292 B1 KR101553292 B1 KR 101553292B1 KR 1020130134096 A KR1020130134096 A KR 1020130134096A KR 20130134096 A KR20130134096 A KR 20130134096A KR 101553292 B1 KR101553292 B1 KR 101553292B1
- Authority
- KR
- South Korea
- Prior art keywords
- olfactory
- present
- preventing
- camp
- equol
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract description 12
- 206010034018 Parosmia Diseases 0.000 title description 3
- 235000019555 hyperosmia Nutrition 0.000 title description 3
- ADFCQWZHKCXPAJ-GFCCVEGCSA-N equol Chemical compound C1=CC(O)=CC=C1[C@@H]1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-GFCCVEGCSA-N 0.000 claims abstract description 14
- 235000019126 equol Nutrition 0.000 claims abstract description 14
- ADFCQWZHKCXPAJ-UHFFFAOYSA-N indofine Natural products C1=CC(O)=CC=C1C1CC2=CC=C(O)C=C2OC1 ADFCQWZHKCXPAJ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004480 active ingredient Substances 0.000 claims abstract description 11
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- 230000036541 health Effects 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 5
- 208000026935 allergic disease Diseases 0.000 claims abstract description 4
- 230000009610 hypersensitivity Effects 0.000 claims abstract description 4
- 230000000638 stimulation Effects 0.000 claims description 13
- 230000003491 cAMP production Effects 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 238000000034 method Methods 0.000 claims description 3
- 230000035945 sensitivity Effects 0.000 claims description 2
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000004556 brain Anatomy 0.000 abstract description 5
- 239000002304 perfume Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 230000035807 sensation Effects 0.000 abstract description 3
- 230000004044 response Effects 0.000 abstract description 2
- 239000000021 stimulant Substances 0.000 abstract 1
- RRAFCDWBNXTKKO-UHFFFAOYSA-N Eugenol Natural products COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 24
- 102000005962 receptors Human genes 0.000 description 19
- 108020003175 receptors Proteins 0.000 description 19
- 210000004027 cell Anatomy 0.000 description 18
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 14
- 239000005770 Eugenol Substances 0.000 description 14
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 14
- 229960002217 eugenol Drugs 0.000 description 14
- 235000019645 odor Nutrition 0.000 description 12
- 102000012547 Olfactory receptors Human genes 0.000 description 7
- 108050002069 Olfactory receptors Proteins 0.000 description 7
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 5
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 230000014509 gene expression Effects 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 102000030621 adenylate cyclase Human genes 0.000 description 2
- 108060000200 adenylate cyclase Proteins 0.000 description 2
- 229910001424 calcium ion Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- ZQSIJRDFPHDXIC-UHFFFAOYSA-N daidzein Chemical compound C1=CC(O)=CC=C1C1=COC2=CC(O)=CC=C2C1=O ZQSIJRDFPHDXIC-UHFFFAOYSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 150000002515 isoflavone derivatives Chemical class 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000002569 neuron Anatomy 0.000 description 2
- 210000004415 olfactory epithelial cell Anatomy 0.000 description 2
- 210000001706 olfactory mucosa Anatomy 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 108090000312 Calcium Channels Proteins 0.000 description 1
- 102000003922 Calcium Channels Human genes 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 208000004356 Hysteria Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 208000017657 Menopausal disease Diseases 0.000 description 1
- 206010027304 Menopausal symptoms Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000000723 chemosensory effect Effects 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 208000012839 conversion disease Diseases 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 150000001949 daidzein Chemical class 0.000 description 1
- 235000007240 daidzein Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000024924 glomerular filtration Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000037315 hyperhidrosis Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000007781 pre-processing Methods 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
본 발명은 이퀄을 유효성분으로 함유하는 후각과민증 예방 또는 치료용 약학 조성물에 관한 것이다. 또한, 본 발명은 이퀄을 유효성분으로 함유하는 후각과민증 예방 또는 개선용 건강기능식품에 관한 것이다. 또한, 본 발명은 이퀄을 함유하는 악취 억제용 방향제 조성물에 관한 것이다. 본 발명의 이퀄을 함유하는 조성물은 후각 자극에 의한 cAMP의 생성을 억제 내지 감소시켜 다양한 후각 자극 물질에 대해 뇌에서 냄새 인지를 못하게 하는 역할을 한다.The present invention relates to a pharmaceutical composition for preventing or treating olfactory hypersensitivity comprising an equol as an active ingredient. The present invention also relates to a health functional food for preventing or ameliorating olfactory sensation containing an equol as an active ingredient. The present invention also relates to a fragrance-suppressing perfume composition containing an equal. The composition containing the equol of the present invention inhibits or reduces the production of cAMP by the olfactory stimulus, thereby preventing the odor from the brain in response to various olfactory stimulants.
Description
본 발명은 이퀄(equol)을 유효성분으로 함유하는 후각과민증 예방 또는 치료용 약학 조성물에 관한 것이다. 또한, 본 발명은 이퀄을 유효성분으로 함유하는 후각과민증 예방 또는 개선용 건강기능식품에 관한 것이다. 또한, 본 발명은 이퀄을 함유하는 악취 억제용 방향제 조성물에 관한 것이다.The present invention relates to a pharmaceutical composition for preventing or treating olfactory sensitization containing an equol as an active ingredient. The present invention also relates to a health functional food for preventing or ameliorating olfactory sensation containing an equol as an active ingredient. The present invention also relates to a fragrance-suppressing perfume composition containing an equal.
냄새의 인지는 다양한 후각 자극 물질이 후각 수용체와 결합하면서 시작되어 아데닐산 시클라아제(adenylyl cyclase)를 활성화시켜 cAMP(cyclic AMP)의 농도를 증가시키고, 증가된 cAMP가 후각 신경세포 내의 칼슘 농도 증가를 유발함으로써 후각 신경세포의 세포막 전위를 변화시켜 화학적인 신호를 전기적 신호로 변환하고 뇌에 전달된 후 인지하는 과정으로 이루어진다. 즉, 공기 중의 냄새 분자가 후각 상피 세포의 세포막에 존재하는 후각 수용체와 결합하면, Golf(olfactory G protein)을 우선적으로 활성화시키고 ,곧이어 AC3 (type III adenylyl cyclase)를 활성화시킨다. AC3는 후각 세포 내에서 ATP로부터 cAMP의 생성을 촉진시키고, 칼슘 이온 채널을 활성화시켜서 궁극적으로 뇌로 신호를 전달하여 냄새 분자를 인식하는 작용을 하게 된다.The perception of odor begins with binding of various olfactory stimuli to olfactory receptors, activating adenylyl cyclase to increase the concentration of cAMP (cyclic AMP), and increasing cAMP to increase the concentration of calcium in the olfactory neurons And then converting the chemical signal into electrical signal by changing the cell membrane potential of the olfactory neuron and recognizing it after being transmitted to the brain. That is, when the odor molecules in the air are combined with the olfactory receptors present in the olfactory epithelial cell membranes, G olf (olfactory G protein) is preferentially activated and then AC 3 (type III adenylyl cyclase) is activated. AC 3 promotes the production of cAMP from ATP in the olfactory cell, activates the calcium ion channel, and ultimately transmits the signal to the brain, thereby recognizing the odor molecule.
사람의 경우 대략 1,200 종류의 후각 수용체 이소폼(isoform)이 존재하는 것으로 보고되었고, 이는 인간이 가진 유전자의 약 3 %를 차지하고 있다. 단일 후각 수용체가 담당하는 냄새 분자는 2, 3 가지 정도이며, 약 100여 가지 후각 수용체의 조합에 따라 사람은 1 만 가지 정도의 냄새(또는 냄새 분자)를 구별할 수 있게 된다. 후각 수용체는 후각 상피세포에서 주로 발현되는 것으로 알려져 있지만, 최근 연구에 의하면 후각-유사 화학감각 신호(olfactory-like chemosensory signaling)이 후각 상피조직 이외의 다른 생체 조직에서도 일어난다는 보고가 있다. 즉, 후각 수용체, 후각-관련 AC3 및 Golf 유전자들은 후각 상피세포뿐 아니라 신장 조직에서도 발현되어 레닌(rennin) 분비 및 사구체 여과율을 조절하는데 관여함이 밝혀졌다.In humans, approximately 1,200 olfactory receptors are reported to be isoforms, accounting for about 3% of human genes. A single olfactory receptor is responsible for about two or three odor molecules. A combination of about 100 olfactory receptors allows humans to distinguish about 10,000 odors (or odor molecules). Although olfactory receptors are known to be mainly expressed in olfactory epithelial cells, recent studies have reported that olfactory-like chemosensory signaling occurs in other tissues other than olfactory epithelium. That is, the olfactory receptor, olfactory-related AC 3, and G olf genes are expressed not only in the olfactory epithelium but also in the kidney tissues, and are involved in regulating renin secretion and glomerular filtration rate.
후각과민증(hyperosmia)이란 고후각증이라고도 하며, 후각이 항진되고 냄새를 강하게 느껴 불쾌감을 느끼는 후각 장애의 일종이다. 심할 때에는 오심, 구토, 두통 등의 증상을 수반한다. 그 원인은 히스테리, 신경쇠약, 임신, 월경 등에 기인한 경우가 많다.Hyperosmia (hyperosmia), also known as hyperhidrosis, is a type of olfactory disorder that feels uncomfortable due to a strong sense of smell. In severe cases, symptoms such as nausea, vomiting and headache accompany. The cause is often caused by hysteria, nervous breakdown, pregnancy, and menstruation.
한편, 이퀄(equol, 4',7-이소플라반디올)은 대두의 주요 이소플라본의 하나인 다이드제인(daidzein)의 장내 대사 산물로서 하기 구조식으로 표현될 수 있다.Meanwhile, equol (4 ', 7-isoflavandiol) is an intestinal metabolite of daidzein, one of the major isoflavones of soybean, and can be expressed by the following structural formula.
이퀄은 전립선암, 골다공증, 갱년기 장애, 탈모, 알레르기, 피부의 노화 등 다양한 질환에 대한 효과가 알려져 있다. 예를 들어, 국제공개공보 WO 2012/107905에는 이퀄의 폐경기 증후군의 치료 및 예방 용도에 대해 개시되어 있다. 이는 다이드제인이 이퀄로 변환함으로써 이소플라본의 여성 호르몬 유사의 생리 작용이 강해지기 때문인 것으로 알려져 있다.EQUAL is known for its effects on various diseases such as prostate cancer, osteoporosis, menopausal disorders, hair loss, allergies and skin aging. For example, International Publication No. WO 2012/107905 discloses the therapeutic and prophylactic uses of Equal menopausal syndrome. It is known that the conversion of daidzein to equals is due to the stronger physiological effects of isoflavones in female hormone-like.
하지만, 이퀄의 후각 관련 작용에 대해서는 전혀 알려진 바 없다.However, it is not known at all about the olfactory-related action of Equals.
본 발명에서는 후각과민증을 근본적으로 치료하거나 또는 악취로 인한 고통을 경감시키는 것을 목적으로 한다. 특히, 냄새를 일으키는 활성 성분 자체를 저해하는 것이 아니라 뇌에서 냄새 인지를 근본적으로 감소시키는 기술을 개발하고자 하였다.The present invention aims at fundamentally treating olfactory sensitization or alleviating pain caused by odor. In particular, it was intended to develop a technique to fundamentally reduce the odor of the brain rather than to inhibit the odorous active ingredient itself.
이에 본 발명자들은 상기와 같은 목적을 달성하기 위하여 예의 연구를 거듭한 결과, 후각 인지 과정 중 이퀄이 후각 자극에 의한 cAMP 생성을 억제 또는 감소시키는 것을 발견하여 본 발명을 완성하기에 이르렀다.Accordingly, the inventors of the present invention have conducted intensive studies to achieve the above object, and as a result, discovered that cAMP production by citalopram stimulation is inhibited or reduced during olfactory cognitive process, thus completing the present invention.
본 발명의 이퀄을 함유하는 조성물은 후각 자극에 의한 cAMP의 생성을 억제 내지 감소시켜 다양한 후각 자극 물질에 대해 뇌에서 냄새 인지를 못하게 하는 역할을 하므로, 후각과민증 치료나 악취 제거용 방향제 등의 용도로 이용 가능하다.The composition containing the equol of the present invention suppresses or reduces the production of cAMP by the olfactory stimulus and serves to inhibit the odor from the brain in response to various olfactory stimuli, Available.
도 1은 본 발명의 실시예에 따른 유진올 수용체 발현 벡터의 일 제조예를 나타낸 것이다.
도 2는 유진올 수용체 발현 벡터를 세포에 도입한 후 유진올 수용체의 발현 정도를 확인한 것이다.
도 3은 유진올 자극에 따른 유진올 수용체 발현 세포에서의 cAMP 발현 정도를 나타낸 것이다.
도 4는 유진올 자극에 따른 유진올 수용체 발현 세포에서의 CREB의 인산화 정도를 나타낸 것이다.
도 5는 이퀄 전처리 후 유진올 자극에 따른 유진올 수용체 발현 세포에서의 cAMP 발현 정도를 나타낸 것이다.
도 6은 이퀄 전처리 후 유진올 자극에 따른 유진올 수용체 발현 세포에서의 칼슘의 양을 나타낸 것이다.
도 7은 이퀄 전처리 후 유진올 자극에 따른 유진올 수용체 발현 세포에서의 CREB의 인산화 정도를 나타낸 것이다.1 shows a preparation example of an eugenol receptor expression vector according to an embodiment of the present invention.
FIG. 2 shows the expression level of the euginol receptor after introducing the euginol receptor expression vector into the cells.
FIG. 3 shows the degree of cAMP expression in the eugenol receptor-expressing cells according to the eugenol stimulation.
FIG. 4 shows the degree of phosphorylation of CREB in euginol receptor-expressing cells according to eugenol stimulation.
FIG. 5 shows the degree of cAMP expression in the euginol receptor-expressing cells following eugenol stimulation after the equal pretreatment.
FIG. 6 shows the amount of calcium in the euginol receptor-expressing cells according to the eugenol stimulation after the equal pretreatment.
Figure 7 shows the degree of phosphorylation of CREB in euginol receptor-expressing cells following eugenol stimulation after equal pretreatment.
이하, 본 발명을 상세히 설명하기로 한다. 다만, 본 발명은 다양한 형태로 변경되어 구현될 수 있으며, 여기에서 설명하는 구현예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail. However, it should be understood that the present invention may be embodied in many other specific forms without departing from the spirit or essential characteristics thereof.
일 측면에서 본 발명은 이퀄(equol)을 유효성분으로 함유하는 후각과민증 예방 또는 치료용 약학 조성물에 관한 것이다.In one aspect, the present invention relates to a pharmaceutical composition for preventing or treating olfactory hypersensitivity comprising equol as an active ingredient.
본 발명에 따른 약학 조성물은, 각각 통상적인 방법에 따라 산제, 과립제, 정제, 캡슐, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 멸균 주사용액, 사전 충전식 주사(pre-filled syringe) 용액제의 형태 또는 동결건조(lyophilized)된 형태로 제형화할 수 있으나, 이에 제한되지는 않는다.The pharmaceutical composition according to the present invention may be formulated into oral compositions such as powders, granules, tablets, capsules, suspensions, emulsions, syrups and aerosols, external preparations, suppository syringes, pre-filled syringes ) Solution form, or a lyophilized form, but the present invention is not limited thereto.
제형화할 경우에는 통상 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 제조될 수 있다. 경구 투여를 위한 고형 제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형 제제는 상기 유효 성분에 적어도 하나 이상의 부형제, 예컨대, 전분, 칼슘 카르보네이트, 수크로오스, 락토오스, 젤라틴 등을 혼합하여 제조할 수 있다. 또한, 단순한 부형제 이외에도 마그네슘 스테아레이트, 탈크와 같은 윤활제도 사용될 수 있다.In the case of formulation, it may be prepared using diluents or excipients such as fillers, extenders, binders, humectants, disintegrants, surfactants and the like which are usually used. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one or more excipients such as starch, calcium carbonate, sucrose, lactose, gelatin, . In addition to simple excipients, lubricants such as magnesium stearate and talc may also be used.
경구 투여를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데, 통상적으로 사용되는 단순 희석제인 물, 액체 파라핀 이외에 다양한 부형제, 예컨대 습윤제, 감미제, 방향제, 보존제 등이 함께 포함될 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성 용제, 현탁제, 유제, 동결건조 제제, 좌제 등이 포함된다.Examples of the liquid preparation for oral administration include suspensions, solutions, emulsions and syrups. Various excipients such as wetting agents, sweetening agents, fragrances, preservatives, etc. may be included in addition to water and liquid paraffin which are simple diluents commonly used have. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried preparations, suppositories, and the like.
본 발명의 약학 조성물의 바람직한 투여량은 환자의 상태 및 체중, 증상의 정도, 약물 형태, 투여 경로 및 기간에 따라 적절하게 선택될 수 있다. 본 발명의 조성물은 유효 성분이 1 일 0.2 ㎎/㎏ 내지 200 ㎎/㎏으로 투여되도록 하는 것이 최적의 효능을 위해 바람직하다. 투여는 하루에 한번 투여할 수도 있고 수회 나누어 투여할 수도 있으나, 이에 한정되지 않는다.The preferred dosage of the pharmaceutical composition of the present invention can be appropriately selected depending on the condition and the weight of the patient, the degree of symptoms, the drug form, the administration route and the period. It is preferable for the composition of the present invention that the active ingredient is administered at a dose of 0.2 mg / kg to 200 mg / kg per day for optimal efficacy. The administration may be carried out once a day or divided into several doses, but is not limited thereto.
본 발명의 약학 조성물은 후각과민증의 예방 또는 치료에 이용될 수 있다. 또한, 본 발명의 약학 조성물은 후각 자극에 의해 상승된 cAMP이나 칼슘 이온의 억제와 관련되거나 관련될 수 있는 비제한적인 질환의 예방 또는 치료에 이용되는 것을 배제하지 않는다.The pharmaceutical composition of the present invention can be used for preventing or treating olfactory sensitization. In addition, the pharmaceutical compositions of the present invention do not preclude the use in the prevention or treatment of non-limiting diseases that may be associated with or associated with the inhibition of elevated cAMP or calcium ions by olfactory stimulation.
다른 측면에서 본 발명은 이퀄을 유효성분으로 함유하는 후각과민증 예방 또는 개선용 건강기능식품에 관한 것이다.In another aspect, the present invention relates to a health functional food for preventing or ameliorating an olfactory sensation containing an equol as an active ingredient.
본 발명의 건강기능식품은, 비제한적으로 각종 음료, 껌, 차, 과자, 비타민 복합체, 건강 보조식품 등의 형태로 제조될 수 있다.The health functional food of the present invention can be manufactured in various forms such as, but not limited to, various drinks, gum, tea, confectionery, vitamin complex, health supplement and the like.
본 발명의 건강기능식품의 바람직한 섭취량은 섭취자의 상태 및 체중, 증상의 정도, 식품 형태, 섭취 기간에 따라 다르며 적절하게 선택될 수 있다. 본 발명의 건강기능식품은 유효 성분이 1 일 0.2 ㎎/㎏ 내지 200 ㎎/㎏으로 섭취되도록 하는 것이 최적의 효과를 위해 바람직하다.The preferred intake amount of the health functional food of the present invention varies depending on the condition and body weight of the recipient, the degree of symptoms, the type of food, and the period of consumption, and can be appropriately selected. It is preferable for the health functional food of the present invention that the active ingredient is ingested at a dose of 0.2 mg / kg to 200 mg / kg per day for optimum effect.
본 발명의 건강기능식품은 후각과민증의 예방 또는 개선에 이용될 수 있다. 또한, 본 발명의 건강기능식품은 후각 자극에 의해 상승된 cAMP이나 칼슘 이온의 억제와 관련되거나 관련될 수 있는 비제한적인 질환의 예방, 개선, 또는 증상 완화에 이용되는 것을 배제하지 않는다.The health functional food of the present invention can be used for prevention or improvement of olfactory sensitivity. In addition, the health functional food of the present invention does not exclude that it is used for the prevention, improvement, or symptom relief of non-limiting diseases which may be associated with or associated with the inhibition of cAMP or calcium ion elevated by olfactory stimulation.
또 다른 측면에서 본 발명은 이퀄을 함유하는 악취 억제용 방향제 조성물에 관한 것이다. 본 발명의 방향제 조성물에 포함된 이퀄에 의해 악취 혹은 회피하고 싶은 냄새가 있는 공간 내에서 사람이 냄새 인지를 감소 또는 억제할 수 있는 효과가 있다. In another aspect, the present invention relates to a perfume odor control composition containing an equal. The effect of the equalizer contained in the perfume composition of the present invention is to reduce or suppress the odor of a person in a room where there is a bad smell or an odor to be avoided.
하기의 실시예를 통하여 본 발명을 보다 상세하게 설명한다. 그러나 하기 실시예는 본 발명의 내용을 구체화하기 위한 것일 뿐 실시예에 의해 본 발명이 한정되는 것은 아니다.The present invention will be described in more detail with reference to the following examples. However, the following examples are for the purpose of illustrating the present invention and are not intended to limit the scope of the present invention.
[실시예][Example]
유진올Eugene Ol (( eugenoleugenol ) 수용체 과발현 세포주의 제조) Receptor over-expressing cell line
후각 자극 물질인 유진올의 cAMP의 증가와 이퀄의 cAMP 생성 억제 효과를 확인하기 위하여 먼저 유진올 수용체 과발현 세포주를 제조하였다. AGS 세포의 핵에 Lipofectamine2000(Invitrogen사 제조)을 이용하여 4 ㎍의 유진올 수용체 발현 벡터를 전달시켜 발현을 유도하였다. 약 48 시간 동안 10% FBS를 포함한 RPMI-1640 세포 배양액을 이용하여 5% CO2, 37℃ 세포배양기에서 배양시켰다. 제조된 유진올 발현 벡터의 일례를 도 1에 나타내었다. 또한, 유진올 수용체 발현 벡터를 세포에 도입(transfection)한 후 웨스턴 블랏을 이용하여 확인해본 결과 유진올 수용체의 발현이 3 배 정도 증가된 것을 확인하였다(도 2).In order to confirm the increase of cAMP and the inhibition of cAMP production of equals in the olfactory stimulant, euginol receptor overexpressing cell line was first prepared. Expression was induced by transferring 4 ug of the eugenol receptor expression vector to the nucleus of AGS cells using Lipofectamine 2000 (Invitrogen). The cells were cultured in RPMI-1640 cell culture medium containing 10% FBS in a 5% CO 2 , 37 ° C cell culture medium for about 48 hours. An example of the prepared eugenol expression vector is shown in Fig. In addition, transfection of the euginol receptor expression vector into cells and confirmation of Western blotting revealed that the expression of the euginol receptor was increased about 3-fold (FIG. 2).
유진올에 의한 cAMP의 증가를 확인하기 위하여 상기 제조된 유진올 수용체 과발현 세포주에 유진올을 0, 200, 400, 800, 1,600 μM의 농도로 각각 처리하여 cAMP의 농도를 Direct cAMP EIA kit(ENZO Life Sciences사 제조)를 이용하여 측정하였다. 도 3에 나타난 바와 같이, 유진올 자극에 의하여 유진올 수용체 발현 세포에서 cAMP가 증가된 것을 확인하였다. 또한, 도 4에 나타난 바와 같이, 유진올 자극에 의하여 유진올 수용체 발현 세포에서 cAMP 신호 전달 관련 단백질인 CREB(cAMP response element-binding protein)의 인산화가 증가함을 확인하였다.In order to confirm the increase of cAMP by euginol, the prepared euginol receptor overexpressed cell lines were treated with eugenol at concentrations of 0, 200, 400, 800, and 1,600 μM, respectively, and cAMP concentration was measured using a Direct cAMP EIA kit (ENZO Life Ltd.). As shown in FIG. 3, it was confirmed that cAMP was increased in the euginol receptor-expressing cells by the euginol stimulation. In addition, as shown in FIG. 4, it was confirmed that phosphorylation of cAMP response element-binding protein (CREB), a cAMP signal transduction related protein, was increased in euginol receptor-expressing cells by euginol stimulation.
이퀄의Equal cAMPcAMP 생성 억제 확인Confirm generation inhibition
이퀄의 cAMP 생성 억제 효과를 확인하기 위하여 상기 제조된 유진올 수용체 과발현 세포주를 PBS 용액으로 세척한 후, 이퀄을 0, 200, 400, 800 μM의 농도로 첨가하여 30 분 동안 전처리한 다음 유진올을 30 분간 처리한 후 cAMP 농도를 Direct cAMP EIA kit(ENZO Life Sciences사 제조)를 이용하여 측정하였다.The euginol receptor over-expressing cell line prepared above was washed with PBS solution, and then equilibrated at 0, 200, 400, and 800 μM for 30 minutes, After 30 minutes of treatment, the cAMP concentration was measured using a Direct cAMP EIA kit (manufactured by ENZO Life Sciences).
(μM)Eugene All Throughput
(μM)
(μM)Equal pre-processing
(μM)
변화율cAMP concentration
Rate of change
상기 표 1 및 도 5에서 알 수 있듯이 유진올 수용체 과발현 세포주에 유진올을 1,600 μM 처리시 cAMP의 농도는 대조군 대비 2.1배 증가함을 확인하였으며, 이퀄을 전처리한 경우 cAMP의 증가가 억제됨을 확인하였다.As shown in Table 1 and FIG. 5, it was confirmed that the cAMP concentration was increased 2.1 times as compared to the control group when 1,600 μM of eugenol was treated with the euginol receptor overexpressing cell line, and the increase of cAMP was suppressed when the equol was pretreated .
또한, 도 6에 나타난 바와 같이, 유진올 수용체 발현 세포에 이퀄을 전처리한 경우 유진올 자극에 따른 칼슘 증가가 농도의존적으로 감소함을 확인할 수 있었다. 도 7에는 유진올에 의해 증가되는 CREB의 인산화 역시 이퀄을 전처리하는 경우 억제됨을 확인할 수 있었다.In addition, as shown in FIG. 6, it was confirmed that when the eugenol receptor-expressing cells were pretreated equally, the calcium increase due to the euginol stimulation decreased in a concentration-dependent manner. FIG. 7 shows that phosphorylation of CREB, which is increased by eugenol, is also suppressed when pretreating equol.
Claims (6)
후각 자극에 의한 cAMP 생성을 감소시키는 것을 특징으로 하는, 후각과민증 예방 또는 치료용 약학 조성물.The method according to claim 1,
A pharmaceutical composition for the prevention or treatment of olfactory hypersensitivity, characterized in that it reduces cAMP production by olfactory stimulation.
후각 자극에 의한 cAMP 생성을 감소시키는 것을 특징으로 하는, 후각과민증 예방 또는 개선용 건강기능식품.The method of claim 3,
A health functional food for preventing or improving olfactory sensitivity characterized by reducing cAMP production by olfactory stimulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130134096A KR101553292B1 (en) | 2013-11-06 | 2013-11-06 | Composition for preventing or treating hyperosmia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020130134096A KR101553292B1 (en) | 2013-11-06 | 2013-11-06 | Composition for preventing or treating hyperosmia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20150052901A KR20150052901A (en) | 2015-05-15 |
| KR101553292B1 true KR101553292B1 (en) | 2015-09-17 |
Family
ID=53389613
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020130134096A KR101553292B1 (en) | 2013-11-06 | 2013-11-06 | Composition for preventing or treating hyperosmia |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101553292B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010501485A (en) | 2006-08-18 | 2010-01-21 | ブリガム・ヤング・ユニバーシティ | Use of equol to prevent or treat neuropsychiatric or neurodegenerative diseases or disorders |
| JP2012135219A (en) | 2010-12-24 | 2012-07-19 | Daicel Corp | Method for producing equol, equol-producing composition, food, food additive and medicine |
-
2013
- 2013-11-06 KR KR1020130134096A patent/KR101553292B1/en active IP Right Grant
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2010501485A (en) | 2006-08-18 | 2010-01-21 | ブリガム・ヤング・ユニバーシティ | Use of equol to prevent or treat neuropsychiatric or neurodegenerative diseases or disorders |
| JP2012135219A (en) | 2010-12-24 | 2012-07-19 | Daicel Corp | Method for producing equol, equol-producing composition, food, food additive and medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150052901A (en) | 2015-05-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101987639B1 (en) | Novel strain of Fusidium coccineum spp., and composition for improving skin beauty comprising a culture solution of the strain | |
| KR101997060B1 (en) | Composition for prevention or treatment of muscular disorder, or improvement of muscular functions comprising fermented deer antler | |
| EP2995304B1 (en) | Germinated and fermented bean extract and cosmetic or food use of a germinated and fermented bean extract | |
| CN105658227B (en) | Composition for preventing and treating cancer-induced fatigue containing processed ginseng powder or processed ginseng extract with increased ginsenoside content | |
| KR101898688B1 (en) | Composition for preventing, treating or improving muscle atrophy comprising complex extracts | |
| JP2011195503A (en) | Protein glycation inhibitor | |
| KR20170010303A (en) | A pharmaceutical composition comprising extract from flower of Rosa rugosa for preventing or treating IL-6-mediated disease | |
| KR101770036B1 (en) | Composition comprising Schizandrae Fructus extract asan effective component for preventing and treatingarthritis | |
| KR20210047594A (en) | Compositions for reinforcing skin barrier and improving atopic dermatitis using hydrangenol or phyllodulcin as an active ingredient | |
| JP2010024222A (en) | Collagen production promoter, hyaluronic acid production promoter, and collagen production and hyaluronic acid production promoter | |
| KR101553292B1 (en) | Composition for preventing or treating hyperosmia | |
| KR101716801B1 (en) | Food composition against metabolic disease or pharmaceutical composition against metabolic disease containing 5-(3',4'-Dihydroxyphenyl)-gamma-valerolactone and 5-(3',4'-Dihydroxyphenyl)-gamma-valerolactone derivatives | |
| KR20160069737A (en) | COMPOSITION COMPRISING METHYLATED CATECHIN FOR ACTIVATING Sirt-1 GENE | |
| JP2008162927A (en) | Nerve cell-protecting agent, medicinal composition containing the same, cosmetic composition and food | |
| KR101679811B1 (en) | Composition for preventing or treating hyperosmia containing piper nigrum extract | |
| KR20220036304A (en) | Composition for anti-obesity comprising dihydrocaffeic acid | |
| KR101830395B1 (en) | Composition comprising squalene for enhancement of muscle function and prevention of muscle damage | |
| KR101392177B1 (en) | Composition comprising 3,3'-diindolylmethane for preventing and treating hyperosmia | |
| KR101607861B1 (en) | Composition for preventing or treating hyperosmia | |
| KR101614144B1 (en) | Composition for preventing or treating hyperosmia containing piperine or salt thereof | |
| KR101769972B1 (en) | A composition for improving, preventing and treating pulmonary disease comprising herb extract | |
| KR102362024B1 (en) | Composition for anti-obesity comprising phenylpropionylglycine | |
| JP6969041B2 (en) | Vascular Endothelial Nitric Oxide Synthetic Enzyme Production Promoter and Oral Composition | |
| KR101892659B1 (en) | Pharmaceutical composition or functional food containing malaxinic acid for improvement of insulin sensitivity | |
| KR20220026640A (en) | Composition comprising an ginsenoside F1 extract for improving memory impairments |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |